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Na:K ratio Sodium : potassium ratio 
D.W Distal water 
W/V Weight/ per volume 
KI Kidney index 
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UFR Urine flow rate 
BPU Blood perfusion unit 
PP tubing Polypropylene tubing 
Abs. Absorbance 
Conc. Concentration 
Std Standard 
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KESAN PEMBERIAN HIDROGEN SULFIDA (H2S) KE ATAS KEPEKATAN 
NUKLEAR FAKTOR KAPPA-B (NF-KB) DALAM PLASMA DAN 
MOLECUL-1 LEKATAN INTERSEL (ICAM-1) DI DALAM MODEL TIKUS 
YANG MENGALAMI  KECEDERAAN REPERFUSI ISKEMIA GINJAL 
ABSTRAK 
 Kajian ini menyelidik kesan pemberian penderma hidrogen sulfida (H2S), 
sodium hidrosulphida (NaHS) secara eksogenous ke atas kepekatan nuklear faktor 
kappa-B (NF-kB) dan molekul-1 intersel (ICAM-1) dalam kecederaan iskemia 
reperfusi ginjal  di dalam tikus normotensif Wistar Kyoto (WKY) tanpa kegagalan 
ginjal (NRF) dan dengan kegagalan ginjal (RF) serta hipertensi aruhan L-nitro-
arginin-methil-ester (L-NAME) di dalam tikus tanpa kegagalan ginjal (NRF) dan 
dengan kegagalan ginjal (NRF). NaHS telah disuntik secara  intraperitoneal pada dos 
56 µmol/kg setiap hari selama 35 hari. Hipertensi telah diaruh di dalam tikus WKY 
dengan memulakan pemberian L-NAME secara oral dalam air minuman pada hari ke 
8 dalam protokol kajian ini pada dos 40mg/kg selama 28 hari. Penyakit kegagalan 
ginjal akut (ARF) telah diaruh dengan suntikan tunggal cisplatin secara 
intraperitoneal pada dos 5 mg/kg. Penghalang cistationin gama liase (CSE) dL-
propargilglicin (PAG) telah diberi pada hari ke-36 (hari eksperimen akut) secara 
suntikan tunggal intraperitoneal pada dos 50mg/kg. Haiwan telah dibahagikan 
kepada 4 kumpulan utama (i)WKY, (ii) L-NAME, (iii) WKY-RF dan (iv) L-NAME-
RF. Semua kumpulan-kumpulan tersebut telah dipecahbahagikan kepada tiga 
kumpulan kecil lagi iaitu (i) kumpulan kawalan, (ii) kumpulan rawatan NaHS dan 
(iii) kumpulan yang diberi PAG. Eksperimen kawalan masa juga telah dilakukan 
dengan menjalankan eksperimen sham di dalam kumpulan-kumpulan WKY-SHAM 
dan L-NAME-SHAM dimana iskemia tidak diaruh. Parameter-parameter data 
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fisiologi, hemodinamik sistemik dan fungsi ginjal telah diambil pada  hari ke-0, 21 
dan 35 di samping pengukuran H2S di dalam plasma pada hari ke-0, 21 dan 36 
kajian. Hemodinamik sistemik, tekanan darah kortikal ginjal (RCBP), halaju 
gelombang denyutan (PWV), parameter fungsi ginjal, penanda tekanan oksidatif, 
kepekatan ICAM-1 dan NF-kB juga telah diukur pada hari akut eksperimen (hari ke-
36) di fasa pra-iskemia dan fasa reperfusi. Data diberikan sebagai min ± S.E.M dan 
telah dianalisis dengan menggunakan langkah-langkah berulang analisis varians 
(ANOVA) satu-hala dan diikuti dengan ujian pos hoc dengan singnifikasi P<0.05. 
Pra-rawatan dengan NaHS telah membaikpulih parameter fungsi ginjal di dalam 
kumpulan ARF dan menurunkan hipertensi aruhan L-NAME secara signifikan 
(semua adalah P<0.05). Tambahan pula, rawatan dengan NaHS telah 
membaikpulihkan paras kecederaan reperfusi iskemia ginjal (IRI) yang dibuktikan 
dengan pengurangan signifikan oleh penanda tekanan oksidatif (semua adalah 
P<0.05), indeks ginjal dan peningkatan signifikan di dalam RCBP (semua adalah 
P<0.05) yang diikuti IRI ginjal. Pra-rawatan dengan NaHS juga telah menurunkan 
kepekatan ICAM-1 dan NF-kB secara signifikan (semua adalah P<0.05) selepas IRI 
ginjal. Kesimpulannya, H2S mempunyai potensi anti oksidan seperti yang terbukti 
dalam kajian ini dengan menurunkan intensiti tekanan oksidatif yang dimana sebagai 
tindak balas telah menghalang pengaktifan NF-kB. Selain itu, H2S juga mempunyai 
ciri-ciri anti radang yang dibuktikan di dalam kajian ini melalui penurunan 
kepekatan ICAM-1. Oleh itu, penemuan ini menunjukkan bahawa H2S mempunyai 
kedua-dua anti-oksida dan anti-radang yang menyumbang kepada pengurangan 
dalam keterukan kerosakan IRI buah pinggang. 
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EFFECT OF EXOGENOUSLY ADMINISTERED HYDROGEN SULPHIDE 
(H2S) ON PLASMA CONCENTRATION OF NUCLEAR FACTOR-KAPPA B 
(NF-kB) AND INTERCELLULAR ADHESION MOLECULE-1 (ICAM-1) IN 
A RAT MODEL OF RENAL ISCHEMIA REPERFUSION INJURY 
ABSTRACT 
The present study investigated the effect of exogenous administration of 
hydrogen sulphide (H2S) donor, sodium hydrosulphide (NaHS) on the concentration 
of nuclear factor kappa-B (NF-kB) and inter cellular adhesion molecule-1 (ICAM-1) 
in renal ischemia reperfusion injury in normotensive Wistar Kyoto (WKY) non-renal 
failure (NRF) and renal failure (RF) rats as well as L-nitro-arginine-methyl-ester (L-
NAME) induced hypertensive NRF and RF rats. NaHS was administered 
intraperitoneally at a dose of 56 µmol/kg on daily basis for 35 days. Hypertension 
was induced in WKY rats by starting oral administration of L-NAME in drinking 
water on day 8 of the study protocol at a dose of 40 mg/kg for 28 days. ARF was 
induced by single intraperitoneal injection of cisplatin at a dose of 5 mg/kg. 
Cystathionine gamma lyase (CSE) inhibitor dL-propargylglycine (PAG) was 
administered on day 36 (acute experiment day) by single intraperitoneal injection at 
a dose of 50 mg/kg. All the animals were divided into four main groups (i) WKY, 
(ii) L-NAME, (iii) WKY-RF and (iv) L-NAME-RF. All these groups were further 
sub-divided into three sub groups (i) control groups, (ii) NaHS treatment groups and 
(iii) PAG administered groups. Time control experiments were also performed by 
operating sham experiments in WKY-SHAM and L-NAME-SHAM groups in which 
ischemia was not induced. Physiological data, systemic haemodynamics and renal 
functional parameters were measured on days 0, 21 and 35 along with plasma H2S 
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measurement on days 0, 21 and 36 of the study protocol. Similarly systemic 
haemodynamics, RCBP, PWV, renal functional parameters, oxidative stress markers, 
ICAM-1 and NF-kB concentration were also measured on acute experiment day (day 
36) at pre-ischemic phase and reperfusion phase. Data, mean ± SEM were subjected 
to repeated measure one-way ANOVA followed by Bonferroni post hoc test with 
significance at P<0.05. Pre-treatment with NaHS improved renal functional 
parameters in ARF groups as well as decreased significantly (all P<0.05) the L-
NAME induced hypertension. Moreover, pre-treatment with NaHS reduced the 
severity of renal ischemia reperfusion injury (IRI) as evidenced by significant 
reduction (all P<0.05) of oxidative stress markers, kidney index and significant 
increase (all P<0.05) in RCBP following renal IRI. Similarly, pre-treatment with 
NaHS also decreased significantly (all P<0.05) NF-kB and ICAM-1 concentration 
after renal IRI. In conclusion, H2S has anti-oxidant potential as evidenced in the 
present study by reducing the intensity of oxidative stress which in response 
inhibited the activation of NF-kB. Similarly, H2S has also anti-inflammatory 
properties as evidenced in the present study by the down regulation of ICAM-1 
concentration. Hence, these findings indicate that H2S has both anti-oxidant and anti-
inflammatory properties which contribute to a reduction in severity of renal IRI 
damage. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
1.1 Kidney 
1.1.1 Anatomy of the kidney 
  Human beings have a pair of kidneys which are present on each side of the 
spine in the abdominal cavity. The left kidney is located at the vertebral level T12-
L3 in the retroperitoneal space while, the right kidney is slightly lower than the left 
kidney. The position of the left kidney is approximately beneath the diaphragm 
posterior to the spleen. The right kidney is located beneath the diaphragm and 
posterior to the liver. An adrenal gland is present on the top of each kidney. Upper 
parts of the kidneys are partially protected by the 11th and 12th ribs. Both kidneys 
along with their adrenal glands are surrounded by two layers of fats the perirenal and 
the pararenal fat and the renal fascia (Walter & Boron, 2004). The weight of the 
adult male kidney ranges from 125 gm to 170 gm and 115gm to 155 gm in adult 
females. The kidney is approximately 11-14 cm long, 6 cm wide and 4 cm thick 
(Glodny et al., 2009). Kidney is a bean shaped structure consisting of concave and 
convex borders. The depression on the concave surface of the kidney is called the 
renal hilum. At the renal hilum the renal artery and renal vein enters into the kidney 
while, renal vein and the ureter leaves the kidney at this position. (Marieb & Hoehn, 
2007). The cross section of the kidney shows two regions, the outer reddish brown 
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part called cortex and the inner darker brown part is called medulla. Nephron is the 
structural and functional unit of the kidney and extends across the cortex and the 
medulla (Shier, 2003). Each kidney consists of approximately 20 million nephrons. 
Nephron consists of glomerulus and the bowmans capsule and this portion is called 
the renal corpuscle and is located in the cortex. Renal corpuscle is then followed by 
the renal tubules which passes into medullary pyramids (Walter & Boron, 2004). The 
renal tubules consist of the proximal convoluted tubules, loop of henle and distal 
convoluted tubules. Tip of each pyramid empties the urine into the minor calyx 
which further empties urine into the major calyces and finally the major calyces 
empties urine into renal pelvis and then the ureter (Drake et al., 2005). Right and left 
renal artery supplies blood directly from the abdominal aorta into the respective 
kidneys. Despite small size of the kidneys they still receive approximately 20 % of 
the cardiac output. Each of the renal arteries divides into segmental arteries which 
branch further into the interlobar arteries which enter into the renal capsule and 
further extend into the renal columns. The arcuate arteries receive blood from the 
interlobar arteries that extend across the surface of the medulla and cortex. Each of 
the arcuate artery empties into various interlobular arteries which further extend into 
the afferent arterioles and these arterioles supplies blood into the glomeruli (Walter 
& Boron, 2004). Once the blood is filtered it passes through small venules followed 
by interlobular veins. From these veins blood is supplied to arcuate veins and then to 
interlobar veins which finally empty into the renal vein. Blood from both renal veins 
returns into inferior vena cava. (Applegate, 2000; Meyer et al., 2004; Vander, 1995).  
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Figure 1.1: Anatomy of the human kidneys. This picture has been adopted from 
Gray, Henry. 1918. Anatomy of the human body (Gray, 1918). 
 
1.1.2 Renal physiology 
 The function of the kidneys is to excrete a wide range of waste products 
produced by the process of metabolism like urea, nucleic acid and uric acid. Kidneys 
are also responsible for the reabsorption of many vital nutrients like glucose and 
amino acids. Kidneys play a key role in the acid base homeostasis and hormones like 
erythropoietin is also produced by the kidneys (Dantzler, 1989). Kidneys play a vital 
role in the regulation of blood pressure through the renin angiotensin aldosterone 
system (Hall & Guyton, 2011). Kidneys contribute in maintaining blood pressure 
along with nervous, cardiovascular and endocrine systems (Germann et al., 2005). 
Nephron is responsible for the process of filtration followed by reabsorption and 
finally secretion. The process of filtration takes place at the renal corpuscle. From 
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the blood larger proteins and various cells get filtered in the process of filtration. 
Thus, the glomerulus filtrate is produced which finally forms the urine. The 
production of the ultra-filtrate is approximately 180 liters per day of which a large 
portion is reabsorbed by the kidneys. Thus the production of urine is only about 2 
liters a day (Guyton, 1991). 
 
1.2 Ischemia reperfusion injury 
1.2.1 Ischemia 
  It is a condition in which blood supply to an organ or tissue is reduced or 
restricted. This results in deficiency of oxygen and glucose supply which is 
necessary for the process of cellular metabolism (Siemionow & Arslan, 2004). 
Ischemic injury is the stoppage or interruption in the arterial blood supply with the 
sudden oxygen shortage to the cells. Thus hypoxia is produced along with 
augmentation of metabolic products (Kosieradzki & Rowinski, 2008).  
There are different types of ischemia like (a) myocardial ischemia, (b) 
cerebral ischemia, (c) critical limb ischemia, (d) hepatic ischemia and (e) renal 
ischemia. 
 
1.2.1 (a) Myocardial ischemia 
  It is a condition in which the heart is unable to maintain the balance between 
blood supply and the demand of oxygenated blood to myocardium itself due to 
blockade or narrowing of the coronary arteries (Mohan, 2010). Myocardial ischemia 
is also called ischemic heart disease (IHD). 
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1.2.1 (b) Cerebral ischemia 
  A condition in which the blood supply to the brain is not sufficient to meet 
the needs for the metabolic processes (Ames et al., 1968). Cerebral ischemia is also 
called brain or cerebrovascular ischemia. 
 
1.2.1 (c) Critical limb ischemia 
 It is the condition in which there is insufficient blood supply to the hands, 
legs and feet due to severe blockade of the arteries. As a result there is pain at rest in 
the form of continuous burning sensation of the legs or feet (Schanzer & Conte, 
2010). There are also sometimes ischemic skin ulcers and even gangrene (Minar, 
2009). 
 
1.2.1 (d) Hepatic ischemia 
           It is the condition in which there is interruption of blood supply to the liver as 
a result the liver does not receive enough blood supply or oxygen (Lentsch et al., 
2000). 
 
1.2.1 (e) Renal ischemia 
 Renal ischemia is the condition in which there is complete cut off or reduced 
blood supply thus, a hypoxic state is developed in the kidneys and due to this 
insufficent oxygen the injury is initiated by the breakdown of ATP. As a result of 
this, adenosine and other metabolic products of nucleotides move out of the cells 
causing ATP production to be delayed once the blood is reperfused back (Gaudio et 
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al., 1986). Functional and structural integrity of all cells is dependent upon cellular 
tight junctions and microfilaments and its functioning requires a continuous supply 
of energy. Once the energy supply is stopped protein subunits breakdown and they 
leave the tight junction of the cells and cellular microfilaments (Hays, 1992). There 
is evidence that the concentration of free intercellular ions increases during ischemia 
(Lee & Allen, 1992) and the injury to kidneys caused by the ischemic condition is 
the main reason for acute renal failure (Basile et al., 2003). Various organ 
transplantation failures are due to this ischemic damage (Wolfs et al., 2005). Some of 
the effects of ischemia at the cellular level are: altered membrane potential, changes 
in ion distribution, cytoskeletal disorganization, cellular swelling, cellular acidosis, 
increased hypoxanthine production and decreased phosphocreatinine, glutathione 
and ATP production (Collard & Gelman, 2001). 
 
1.2.2 Reperfusion injury 
 Reperfusion injury is the damage induced by the reperfused blood as it is 
restored after the ischemic phase. Reperfusion injury is the result of cell activation 
and the injury occurred during ischemia (Bilzer et al., 1999). In reperfusion phase the 
permeability of various capillaries and arterioles becomes much more high and thus 
the tissues becomes more susceptible to fluid filtration. After the reperfusion process 
the concentration of reactive oxygen species is increased because they are produced 
in greater quantity by the activated endothelial cells but the nitric oxide production is 
reduced. This imbalance between the reactive oxygen species and nitric oxide 
production initiates the inflammatory response (Carden & Granger, 2000). 
Reperfusion injury is the effective continuation stage of the injury induced by 
ischemia. This injury may occur within hours or days after ischemia. Cellular 
7 
 
necrosis and apoptosis is accompanied together by the cellular regeneration and 
repairing processes which requiring energy. The activation of caspase and liberation 
of cytochrome C occurs as early as 5 minutes after the process of reperfusion (Hoek 
et al., 2003). The concentration of free intercellular calcium ion which was increased 
during early ischemia starts returning back to the normal level. Due to this the cells 
start recovering from early damage done in ischemic phase. But due to continuous 
increase of the calcium ion an irreversible injury starts (Lee & Allen, 1992). After 
reperfusion there is a quick release of free radicals. The main source for the 
production of free radicals is respiratory chain enzymes. Superoxide is formed from 
free oxygen which reacts with reduced ubiquinone. Superoxide is metabolized by 
catalyse to produce hydrogen peroxide or this superoxide is metabolized to hydroxyl 
radical where ferrous or copper acts as catalyst (Kosieradzki & Rowinski, 2008). 
After reperfusion, the superoxide free radical .O-2 is produced in large quantities. This 
reactive superoxide specie produces more hydroxyl radical .OH, through Fenton and 
Haber-Weiss reactions and uses iron as a reaction catalyst (Zweier, 1988).  
                                     O-2 + Fe3+                                           Fe2+ + O2 
                         Fe2+ +H2O2                          Fe3+ + OH- + OH 
 
These highly reactive free radicals cause the peroxidation of the 
mitochondrial and cellular membranes of the phospholipids and hence induce 
endothelial injury in reperfusion phase. This causes an increase in the extent of 
injury of endoplasmic reticulum which causes the production of autophagosomes and 
then cellular degradation. This increases lysosomal activity of the proteases and 
causes further necrosis and aptoposis (Kosieradzki & Rowinski, 2008). Metabolites 
of reactive oxygen species and polymorphonuclear leukocytes have been reported to 
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be involved in the pathophysiology of ischemia reperfusion injury (Zimmerman & 
Granger, 1994). The reactive oxygen species produced during ischemia reperfusion 
injury is responsible for the cellular damage through lipid peroxidation (Jaeschke, 
1998). It has also been cited that one of the most important hypothesis of cellular 
damage by the reactive oxygen species is through inhibition of lipid peroxidation 
(Jaeschke, 2000). Cellular damage caused by the reactive oxygen species is due to 
the degradation and oxidation of proteins, lipid peroxidation and also due to the 
damage of DNA. These redox signalling injuries activates the pathways of 
transduction which in response initiates the process of injury (Fan et al., 1999). It has 
also been hypothesized that xanthine oxidase and mitochondria is a potential source 
of reactive oxygen species formation (Jaeschke, 1996). One study has suggested that 
generation of reactive oxygen species by phagocytic cells may be one source for the 
cellular injury but different types of inflammatory mediators may also be involved in 
the reperfusion injury (Jaeschke et al., 1992). These reactive oxygen species are 
responsible for the cellular damage and also act as second messenger for the 
initiation of inflammation. The major site for the production of reactive oxygen 
species is mitochondria. The consumption of oxygen and production of energy is 
achieved by the electron transport chain. In this transport chain the molecular oxygen 
is reduced to water. The ischemic reperfusion injury in mitochondria is responsible 
for the electron transport chain decoupling. As a result of this decoupling large 
quantity of reactive oxygen species is generated and released (Fan et al., 1999). So, 
reactive oxygen species is an important factor during ischemia reperfusion injury. 
Ischemic reperfusion injury is also a major factor for the increased morbidity and 
mortality in numerous clinical conditions specially in organ transplantation failure 
(Fan et al., 1999).  
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1.3 Renal failure 
 Renal failure is characterized by renal dysfunction in which kidneys are 
unable to perform filtration of waste products in the blood properly (Kajbaf et al., 
2013). There are two major types of renal failure discussed below. 
 
1.3.1 Chronic renal failure 
 Chronic renal failure is a condition which is characterized by the kidney 
injury and glomerular filtration rate becomes lower than 60 mL/min for a period of 
three consecutive months or a period of more than three months. In chronic renal 
failure an irreversible sequence of damages occur which causes last stage kidney 
disease (Parmar, 2002). Chronic kidney injury involves the irreversible loss of 
kidney function involving slow deterioration of parenchymal cells of the kidney 
leading to nephronal damage during this process (Mohan, 2010). 
 
1.3.2 Acute renal failure 
 In acute renal failure (ARF), renal function is affected or declined in a shorter 
span of time between hours to days and may result in kidney failure. The kidney is 
unable to perform excretion of various waste products as well as balance and 
maintenance of electrolytes and fluids (Ympa et al., 2005). Acute renal failure 
involves rapid onset of renal dysfucntion mainly indicated by anuria or oliguria. 
ARF is also characterized by rapid increase of blood creatinine and urea 
concentration and ureamia may also occur subsequently (Mohan, 2010). In acute 
renal failure the concentration of creatinine in serum increases 50 % from the 
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baseline value (Evenepoel, 2004). Various factors which induce ARF are 
hypovolemia, sepsis, liver dysfunction, damaged renal perfusion, vascular blockade 
and drugs (Ympa et al., 2005). Three main causes of ARF has been identified 
(Mohan, 2010) which are discussed below. 
                                   
1.3.2 (a) Pre-renal cause 
 It is a reversible type of renal failure and reduced arterial blood flow to the 
kidneys is the main reason for pre-renal azotaemia (Evenepoel, 2004). It is 
characterized by reversible increase of plasma creatinine and blood urea. Decreased 
renal reperfusion is the cause of pre-renal azotaemia due to which the glomerular 
filtration rate becomes low (Lameire, 2005). It occurs in response to low 
extracellular volume and increased activity of adrenergic receptors and may 
accompany heart failure, sepsis, cirrhosis or nephrosis (Blantz, 1998). 
 
1.3.2 (b) Intra-renal cause 
 In intra renal acute renal failure damage to the renal tissues occurs specially 
to the renal arteries and arterioles. Moreover, it is characterised by injury to 
glomeruli and acute tubular necrosis (ATN) (Mohan, 2010). Various toxins and 
ischemia is mainly responsible for the tubular injury occurring in intra-renal ARF 
(Wali & Henrich, 2002). 
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1.3.2 (c) Post-renal cause 
 Post-renal cause involves blockade to urine flow in the renal tract. This 
obstruction to the flow of urine results from the formation of a mass inside the lumen 
or there may be any external compression on the urinary tract, urethra, ureter or 
bladder which leads to renal infection (Mohan, 2010). 
 
1.3.3 Drugs-induced acute renal failure 
 ARF may be induced by different types of therapeutic agents. Acute 
interstitial nephritis results from various drugs which causes allergic reactions. This 
may further cause inflammation and tubular injury. Therapeutic agents that cause 
ATN involve toxicity to the tubular epithelium directly with the induction of 
inflammation. Some other injuries induced by various medications involves crystal 
nephropathy, acute nephrocalcinosis and osmotic nephropathy (Markowitz & 
Perazella, 2005). Therapeutic agents that cause pre-renal acute renal failure include 
NSAIDS, cyclosporine and diuretics etc (Lameire, 2006). Drugs responsible for the 
post-renal causes of acute renal failure include methysergide, acyclovir, 
sulphonamide and triamterene etc (Perazella, 1999). Majority of drugs and chemicals 
are involved in the induction of intra-renal ARF (Woolfson & Hillman, 2000; Zager, 
1997). Amongst various tubular injuries ATN is the most prominet one that occur 
during intra-renal injury of acute renal failure (Woolfson & Hillman, 2000). Various 
chemical agents and drugs that cause ATN are antibiotics, amphoteracin B, 
aminoglycosides, cyclosporine A, mannitol, cisplatin and polyethylene glycol etc 
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1.3.3 (a) Cisplatin induced acute renal failure 
 Cisplatin belongs to the class of platinum containing anti-cancer drugs used 
for solid malignancy treatment. Cisplatin is also used in the treatment of lung cancer, 
bladder cancer, ovarian cancer, cervical cancer, germ cell tumours, lymphomas and 
sarcomas. Various models of ARF in laboratory animals for different physiological 
and pharmacological studies have been achieved through cisplatin administration 
(Atessahin et al., 2005; Rubera et al., 2013; Tayem et al., 2006). Tubular filtration 
and secretion are mainly responsible for the excretion of cisplatin whereas 
peritubular uptake is responsible for cisplatin accumulation in the kidneys (Annie et 
al., 2005). So, cisplatin does not undergo the process of tubular reabsorption. 
Proximal tubular cells of outer medulla and inner cortex are the main site for 
cisplatin toxicity. Mostly cisplatin-induced renal injury occurs at S3 segment of 
nephrons (Leibbrandt et al., 1995). It has been reported by various studies that renal 
toxicity occurs by injecting single dose of cisplatin. Renal toxicity causes an increase 
in serum creatinine and blood urea nitrogen. Cisplatin renal toxicity induces necrosis 
and apoptosis of proximal convoluted tubules (Dobyan et al., 1980). Cisplatin 
induced renal toxicity causes ATN and sloughing of epithelial cells of the renal 
tubules (Al-Harbi et al., 1995), decreased glomerular filtration rate (Kang et al., 
2004), damage to proximal tubules (Jones et al., 1985) and increased resistance to 
renal blood vessels (Matsushima et al., 1998). Cisplatin induce renal failure also 
involves the role of reactive oxygen species (ROS) specially hydroxyl radicals and 
superoxide anion because it has been reported that oxidative stress is induced by 
cisplatin due to the production of free radicals (Badary et al., 2005; Brahmi et al., 
2012). Increased peroxidation of lipid molecules is also a hallmark of cisplatin 
induced renal toxicty (Paul et al., 1991; Vaziri et al., 2002). It has also been reported 
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that ROS involves in the inhibition of various anti-oxidant enzymes in the kidneys 
(Masuda et al., 1994) and specially affecting the concentration of  renal glutathione 
level (Jin & Lindup, 1993). 
 
1.4 Hypertension 
 Chronic increase of systemic arterial blood pressure above defined limits is 
defined as hypertension. Thus, hypertension is a chronic medical condition 
sometimes also called as high blood pressure or arterial hypertension. The border 
line between normal pressure and hypertension is 140/90 mmHg (Vander & 
Luciano). So, hypertension is sustained increase of systolic blood pressure which 
exceeds 140 mmHg and diastolic blood pressure exceeds 90 mmHg in adults. 
Hypertension is a common cause of various cardiovascular diseases like coronary 
artery disease, cardiac failure and dissecting aortic aneurysm. It is also a risk factor 
for renal insufficiency and stroke (Laurence et al., 2008).  
 
 
 
 
 
 
 
 
 
14 
 
Table 1.1: Classification of hypertension for adults in Malaysia (NHMS 3, 2006)3 
redrawn by using Ms Word office from Clinical Practice Guidelines for Management 
of Hypertension (4th edition) issued in 2013 available online on 
http://www.moh.gov.my/attachments/CPG_Management_of_Hypertension_4th_Edit
ion.pdf  
 
Classification 
  
Systolic B.P (mm Hg) Diastolic B.P (mm Hg) 
Optimal 
 
< 120 and < 80 
Normal 
 
< 130 and < 85 
High normal 
 
130 – 139 and/or 85 – 89 
Hypertension 
 
Stage 1 140 – 159 and/or 90 – 99 
 
Stage II 160 – 179 and/or 100 – 109 
 
Stage III > 180 and/or 
 
> 110 
 
 
1.4.1 Primary hypertension 
 It is the type of hypertension for which the cause or origin is unknown. It is 
also called essential hypertension. Most of the patients having essential hypertension 
have a family history indicating hereditary tendency (Guyton & Hall, 2006). It has 
been citied in various articles that genetics is a key factor in the primary 
hypertension (Feinleib et al., 1977; Longini et al., 1984). Demographical and 
environmental causes are the factors mainly responsible for genetically induced 
hypertension (Oparil et al., 2003). Obesity may also be the cause for the primary 
hypertension (Chiong et al., 2008). 
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1.4.2 Secondary hypertension 
 It is the type of hypertension for which the cause or origin is known (Chiong 
et al., 2008; Guyton & Hall, 2006). About 5-10 % of the population suffer from 
secondary hypertension. The major causes of secondary hypertension are various 
diseases some of them are given as follow. 
 Renal diseases like renal parenchymal disease, renin producing tumor and 
renal vascular disease etc. Cardiovascular diseases like rigidity of aorta and 
coarctation of aorta. Endocrine diseases like hypothyroidism, hyperthyroidism, 
primary aldosteronism and acromegaly etc. Acute stress related hypertension, 
pregnancy related hypertension, obstructive sleep apnea and drugs induced 
hypertension (Chiong et al., 2008). 
 
1.4.2 (a) L-NAME induced hypertension 
 L-nitro-arginine methyl ester (L-NAME) induced hypertension is widely 
used as an animal model for secondary hypertension in various in vivo studies. L-
NAME given orally to the laboratory animals induces hypertension and thus presents 
as a secondary hypertension model in laboratory rats (Khayyal et al., 2002). L-
NAME is a nitric oxide synthase (NOS) inhibitor and chronic treatment with L-
NAME induces arterial hypertension in rats. Systemic blood pressure and vascular 
tone is mainly regulated by the endothelium which is involved in the production of 
various vasodilating and vasoconstricing factors like nitric oxide (NO), angiotensin 
II, endothelins and prostacyclin (Bernatova et al., 2000). Various studies have shown 
that L-arginine is the precursor of NO which mediates various gastrointestinal, 
neural and cardiovascular functions. L-arginine is metabolised to NO by NOS 
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(Mourad et al., 1996). NO in the blood vessels is mainly produced from the isoforms 
of NOS either by endothelial nitric oxide synthase (eNOS) or nitric oxide synthase-3 
(NOS3). More studies have also reported that NO is produced endogenously and its 
continuous genesis plays a key role in the maintenance of vascular and gastric 
integrity (Tepperman & Whittle, 1992; Whittle et al., 1990). Inhibition of platelet 
aggregation, inhibition of neutrophil endothelium adhesion, regulation of apoptosis, 
and vasodilation is mainly induced by NO (Rosselli et al., 1998).  L-NAME inhibits 
eNOS because it is an analogue of the L-arginine and thus competes with it on eNOS 
binding sites (Rees et al., 1990). L-NAME causes the inhibition of eNOS thus 
inactivating NO. It also inhibits nNOS and thus stimulates sympathetic nervous 
system. In order to maintain hypertension L-NAME activates renin-angiotensin 
system (Biancardi et al., 2007). Moreover, various mechanisms of L-NAME induced 
hypertension have also been reported like, L-NAME causes an increase in the level 
of endothelin-1 (Amours et al., 1999) and also blocks Na+K+-ATPase channels 
(Rossoni et al., 2003) and thus contributes to the induction of hypertension. It is also 
documented that L-NAME may act as an antagonist for the muscarinic receptors and 
may also effect the activity of prostaglandins (Buxton et al., 1993). Long term 
treatment with L-NAME in vivo studies show structural changes in the vasculature 
and may also cause myocardial hypertrophy (Usui et al., 1999). Decrease in the 
endogenous production of NO may cause oxidative stress (Kurose et al., 1995; Niu 
et al., 1994). Increased oxidative stress in the rats treated with L-NAME is reported 
further evidenced by increased protein oxidation of the membrane, enhanced 
NADPH oxidase-1 (NOX-1) and NADPH oxidase-2 (NOX-2) and also augmented 
concentration of superoxide dismutase (SOD) which is an anti-oxidant glutathione 
(Bell et al., 2008). Inhibition of NO by L-NAME may cause the production of 
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reactive oxygen species (ROS) specially superoxide anion (O-2) (Kitamoto et al., 
2000). 
 
1.5 Inflammation 
 Inflammation is the local response of the tissues to any injury induced by any 
harmful agent or stimuli and is therefore a defensive mechanism of the body which 
involves the removal of the harmful agents or reducing the chances of spreading of 
these injurious agents (Mohan, 2010). It is the process in which body response to 
various stimuli like irritants, various pathogens and some damaged cells (Ferrero et 
al., 2007). During inflammation there is release of different types of mediators by 
injured or damaged cells in response to heat, trauma or different types of chemicals. 
This response initiates secondary changes in the injured neighbouring tissues and 
this whole physiological response in the tissues is called as the process of 
inflammation (Guyton & Hall, 2006). Inflammation is the protective response of the 
body which is participated by blood vessels, host cells, proteins and different type of 
mediators. This protective effect is carried out by initially diluting, destroying or 
neutralizing the injurious agents (Kumar et al., 2012). The function of inflammation 
is to combat the initial source of the injury done to the cells or tissues to provide 
defense against necrosis and to eradicate various cells or tissues damaged during this 
process. Inflammation also induces repairing of the damaged tissues after the initial 
insult. The area where the inflammation is going on is marked with swelling, 
redness, pain and heat sensation. Inflammation is the natural response of the body 
and referred to as the mechanism of innate immunity (Abbas et al., 2012). The 
ability of the body to induce inflammation is necessary for its survival against 
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various foreign pathogens and different kind of injuries evoked by various stimuli 
like physical injuries, antibodies, various pathogens and different kind of infections. 
The inflammatory process during normal conditions and in various diseased states 
may be induced and maintained without any beneficial effects or may cause some 
noxious consequences (Laurence et al., 2008). The pathophysiology of inflammation 
involves the excessive blood flow to the damaged tissues due to increased 
vasodilation of blood vessels. Inflammation is also characterized by the movement of 
a large number of leukocytes in to the effected tissues. Due to increased permeability 
of the capillaries there is excessive leakage of fibrinogen which results in the 
formation of fluid clotting in interstitial spaces. Various inflammatory mediators 
stimulate the immune system. Thus, with in a period of only a few hours the 
macrophages start engulfing the damaged tissues. But during this defensive process 
they further damage the neighbouring normal tissues (Guyton & Hall, 2006). During 
the process of inflammation there is an initial inflammatory response to different 
inflammatory mediators and the second one is the healing process of the injured 
tissues. So, these steps cause considerable damage to the tissues. Immune system and 
inflammation are the defensive mechanisms of the body and both are interrelated to 
each other. Inflammation results from any immune reaction while activation of 
immune system is a necessary factor before the process of inflammatory response 
(Mohan, 2010). One of the most popular phenomenon of inflammation is the 
"walling off" the surrounding undamaged tissues from the injured tissues. Fibrinogen 
clots block the lymphatic and the interstitial spaces of the damaged area so after a 
shorter period of time there is an increased flow of fluids in these spaces. The 
advantage of walling-off mechanism is that it delays the spreading of various 
pathogens and different injurious products (Guyton & Hall, 2006). Inflammation is 
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characterized by three specific basic phases with each phase involving different 
mechanisms. The initial one is the acute phase of inflammation where an increased 
vasodilation and enhanced permeability of the capillaries occurs. The second one is 
the subacute phase with a delayed inflammatory response that involves migration of 
different phagocytic cells and leukocytes to the inflamed area. Chronic proliferative 
phase is the third and last phase which is characterized by degeneration of the 
tissues. Fibrosis also takes place in this stage (Laurence et al., 2008). Without the 
process of inflammation there will be no monitoring of the infections and will 
worsen with the passage of time. Secondly, without inflammation there will be no 
healing process (Kumar et al., 2012). There are two types of inflammation namely 
acute and chronic inflammation as discussed below. 
 
1.5.1 Acute inflammation 
 Acute inflammation is characterized by the rapid transport of leukocytes and 
plasma proteins to the injurious area. Once the leukocytes are migrated at the site of 
injury they start clearing the area from the invaders and start engulfing and removing 
the necrotic tissues (Kumar et al., 2012). The duration of acute inflammation is very 
short which may be less than a period of two weeks. Acute inflammation is typified 
by plasma and fluid accumulation at the area of injury, platelet activation and 
neutrophil infiltration. Sometime the response of acute inflammation is more serious 
and that is why it is called fulminant acute inflammation (Mohan, 2010). Acute 
inflammation is divided in to two events, vascular and cellular changes. 
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1.5.1 (a) Vascular changes 
 It involves the changes in the vascular capabilities which cause increased 
vasodilation. Vascular changes are also characterized by the enhanced permeability 
of the capillaries which results in the leakage of plasma proteins from the blood 
vessels. Furthermore, vascular changes are accompanied by stimulating endothelial 
cells as a result of this activation leukocytes start adhering to these endothelial cells 
and starts rolling and migration along the blood vessels wall (Kumar et al., 2012).    
 
1.5.1 (b) Cellular events 
 Vascular changes are followed by cellular events which are characterized by 
the infiltration of leukocytes from the wall of blood vessels. After this they enter into 
the injury zone and start gathering in large numbers over there. The gathered 
leukocytes are activated and they start the removal of invaded harmful agents. The 
major leukocytes that participate in the acute inflammation are polymorphonuclear 
leukocytes (neutrophils) (Kumar et al., 2012).    
 Various mediators can induce the response of acute inflammation. Amongst 
them viral, bacterial, parasitic and fungal infections are more common triggers. 
Moreover, different kind of foreign bodies like dirt, crystal deposits and splinters etc 
can also induce acute inflammation. Different chemical substances, physical trauma 
or certain environmental factors may also induce acute inflammation. Numerous 
conditions of ischemia are also responsible for the induction of acute inflammation 
(Kumar et al., 2012).    
 
